I have already indicated that there is no unanimous consent on this point. Before we continue with the points of order being raised, I would like to ask members, if at all possible, to make sure that we use the time of the House efficiently. If members are seeking unanimous consent, I ask that they do attempt to negotiate that in advance with the House leadership from the different parties. That way we can make sure that we use the time efficiently. The hon. member for Barrie—Springwater—Oro-Medonte.

Fortunately, the hon. member is a very credible and capable member and understands that this is a point of debate.

This is a similar point to what was raised by the hon. member for Thornhill, so I am afraid we are entering into debate.

It is always in everybody's interest, and I say this to all members quite sincerely, if members want to raise a point of order, that they get straight to the point of the point of order they want to bring up. Otherwise, when we hear the premise and the introduction, it is often getting into debate and it forces the Chair to say that it is a matter of debate, as opposed to either seeking unanimous consent or raising a point of order. The hon. member should either raise a point of order or seek unanimous consent right away. The hon. member for Calgary Midnapore.

I will invite the hon. member to please sit down because this is clearly a point of debate. The hon. member for New Westminster—Burnaby.

I thank the hon. member for New Westminster—Burnaby for reminding the House of all of the expenses that are required when we do not take the opportunity to negotiate these things in advance. I do ask members to do this. I see that the member for Coast of Bays—Central—Notre Dame is rising to his feet. I do hope that the member will either raise a point of order or get immediately to the request for unanimous consent.

I would remind members that, when they present petitions, they should not indicate whether they are for or against or give an opinion. They should just present the petition.

With regard to Health Canada’s authorization of COVID-19 vaccines, at the time of approval through the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 in 2021: (a) was there evidence that the vaccines stopped people from transmitting the virus to others and, if (i) affirmative, what is the evidence, (ii) negative, what is the evidence for public messaging suggesting that herd immunity was achievable through mass vaccination; (b) why was the early initiative to track seroconversion of Canadians against SARS CoV 2 abandoned and the task force for this dissolved; and (c) why was naturally-acquired immunity not considered an appropriate form of immunity against SARS-CoV-2? With regard to Canada’s G20 commitment to phase out inefficient fossil fuel subsidies and the self-review assessment framework released in July 2023: (a) which tax measures were identified as fossil fuel subsidies and found to be (i) efficient, (ii) inefficient; and (b) which non-tax measures were identified as fossil fuel subsidies and found to be (i) efficient, (ii) inefficient? With regard to Immigration, Refugees and Citizenship Canada and the family-based humanitarian pathway for Sudanese and non-Sudanese nationals due to the ongoing conflict in Sudan, since the December 28, 2023 announcement: (a) how many applications have been (i) received, (ii) accepted, (iii) denied, (iv) pending or under review; (b) what is the breakdown by male and female; (c) what is the breakdown by age range; (d) how many were study permits; (e) how many were open work permits; (f) how many were temporary visitor visas; and (g) how many IMM 5992 statutory declaration forms have been filled out? With regard to March Madness expenditures where government managers make extra purchases in an attempt to spend their entire budget allotment before the end of the fiscal year: what specific measures, if any, are in place to prevent or discourage such spending ahead of the end of the 2023-2024 fiscal year, broken down by the measure that each department or agency is taking? With regard to government funding of the United Nations Relief and Works Agency for Palestine Refugees (UNRWA): (a) what are the transaction dates and amounts of all funding the government provided to UNRWA since January 1, 2023; and (b) what are the scheduled dates and amounts for future transactions of government funding to UNRWA for the remainder of 2024 that will no longer take place due to the government's pause on funding? With regard to audits conducted by the Canada Revenue Agency, broken down by fiscal year from 2015-16 to present: (a) what is the total number of audits conducted on (i) people with disabilities, (ii) First Nations, Inuit, or Métis peoples, (iii) people over the age of 65, (iv) individuals whose net worth is more than $50 million; (b) what is the total number of audits conducted due to (i) excessive health claims, (ii) excessive health travel claims; (c) what is the total value of those audits; and (d) for each of the audits in (a) and (b), what is the total number of audits that resulted in (i) prosecutions, (ii) convictions?

With regard to the government authorization of mRNA COVID-19 vaccines: (a) when did Health Canada (HC), the Public Health Agency of Canada (PHAC), and the National Advisory Committee on Immunization (NACI), receive documentation from Pfizer acknowledging the presence of SV40 enhancer promoter sequence and SV40 poly(A)tail signal sequence in their vaccine BNT162b2; (b) with respect to the documentation related to (a), (i) how can the documentation be accessed, (ii) when was it received by HC, PHAC and NACI, (iii) was this documentation obtained before or after the BNT162b2 vaccine was authorized; (c) has HC asked Pfizer about the safety of the SV40 enhancer promoter sequence and SV40 poly(A)tail signal sequence in their vaccine, and, if not, why not; (d) if the answer to (c) is affirmative, what are the risk analyses that Pfizer did, if any, regarding these SV40 sequences; (e) what amount of SV40 sequences is considered safe (i) in a single Pfizer mRNA vaccine dose for distinct age groups, (ii) for repeated vaccine injections over time per each age group considered; (f) what were HC’s regulatory guidelines surrounding SV40 sequences in a vaccine prior to 2019; (g) what are the current (relevant for the period of 2019-2024) regulatory guidelines surrounding SV40 sequences in a conventional vaccine and in an mRNA vaccine; (h) how does HC know the SV40 fragments are inactive and have no functional role in mRNA vaccines; (i) has HC verified the amount of SV40 enhancer promoter sequence and SV40 poly(A)tail signal sequence in any of the Pfizer or Moderna mRNA vaccines, including the Pfizer XBB, and, if not, why not; (j) if the answer to (i) is affirmative, what was the outcome of this verification and how was this verification done; (k) what is HC’s official position with respect to the increased risk of DNA contaminants getting into human cells, including the cell nucleus, when encapsuled in liposomes, as is the case with the mRNA vaccines; (l) how has HC confirmed with certitude there is no genetic integration (i.e. in vivo transfection into the nucleus of human cells) of DNA plasmid fragments, which may or may not contain SV40 sequences, as found in either mRNA vaccine; (m) does the publicly undisclosed presence of SV40 sequences or any other adulteration (e.g. reverse open reading frames [ORF]) violate the terms and conditions of the Pfizer and Moderna contracts, and, if not, why not; and (n) if the answer to (m) is affirmative, what are the consequences? With regard to cleantech transactions signed by Export Development Canada (EDC), broken down by fiscal year since 2018-19: (a) what are the details of each transaction, including, the (i) date of signing, (ii) country of transaction, (iii) principal counterpart, (iv) EDC product, (v) industry sector, (vi) financial range; and (b) of the transactions in (a), which transactions were intended to support (i) carbon capture, unitization and storage technologies, (ii) blue hydrogen, (iii) grey hydrogen? With regard to Immigration, Refugees and Citizenship Canada and the temporary special measures for extended family in Gaza due to the Israel-Hamas war, since the December 21, 2023 announcement: (a) how many applications have been (i) received, (ii) accepted, (iii) denied, (iv) pending or under review; (b) what is the breakdown by male and female; (c) what is the breakdown by age range; (d) how many were study permits; (e) how many were open work permits; and (f) how many IMM 5992 statutory declaration forms have been filled out? With regard to Immigration, Refugees and Citizenship Canada (IRCC) transferring refugees to Niagara Falls, Ontario, between February 1, 2023 and February 1, 2024: (a) how many have been transferred to Niagara Falls in total; (b) what is the monthly breakdown of the number of refugees transferred to Niagara Falls; (c) which hotels is the government using to lodge refugees in Niagara Falls; (d) how many hotel rooms are currently being occupied by refugees in Niagara Falls; (e) what is the capacity of each hotel room that is being occupied by refugees in Niagara Falls; (f) how many refugees are staying in each hotel room in Niagara Falls; (g) what is the average length of time IRCC expects (i) an individual refugee, (ii) a refugee family, to be lodged in a Niagara Falls hotel room; (h) for all refugees being lodged in government funded Niagara Falls hotel rooms, without identifying names or other personal information, how many days has each refugee stayed; (i) what is the average cost per night that IRCC pays per refugee for staying in a Niagara Falls room; (j) for the night of February 1, 2024, what was the total cost IRCC paid hoteliers to house refugees located in Niagara Falls; (k) what is the average cost that IRCC pays per refugee who lives in a Niagara Falls hotel room for daily meals and refreshments; (I) for the month of January 2024, what was the total cost IRCC paid hoteliers to feed refugees located in Niagara Falls; (m) what are the countries of origin for refugees who have been accommodated in Niagara Falls; (n) what is the breakdown of refugees transferred to or accommodated in Niagara Falls by each country of origin; (o) how much funding was transferred by the federal government to the municipality of Niagara Falls to deal with the influx of refugees in the city; (p) how much funding has been transferred by the federal government to the Region of Niagara to deal with the influx of refugees in the region; (q) how much funding was transferred by the federal government to local not-for-profit, charitable, and non­governmental organizations in Niagara Falls to deal with the influx of refugees in the city; (r) what are the names of the specific not-for-profit, charitable, and non-governmental organizations who have received federal government funding; (s) what is the breakdown of funding for each organization to date; (t) how many more refugees does IRCC currently plan to transfer to or accommodate in Niagara Falls; (u) how many refugees have moved out of government funded hotel rooms in Niagara Falls and into personal accommodations; (v) when does the federal government plan to stop paying for refugee hotel rooms in Niagara Falls; and (w) what are the terms and conditions of the financial agreement that IRCC has with each hotelier located in Niagara Falls that houses refugees and receives federal monies to provide this service? With regard to properties sold by the government since January 1, 2021: what are the details of all properties which have been sold by the government, including, for each, the (i) street address and land location, (ii) city or municipality, (iii) province or territory, (iv) type of property (residential, commercial), (v) description of property, including size of land and square footage of buildings, (vi) date of sale, (vii) price that the property was sold for, (viii) value of the last known municipal property assessment as performed by the province or territory where the property was located in, (ix) buyer? With regard to the approximately $602 million that Indigenous Services Canada spent on medical evacuations in 2022: what is the breakdown of the spending by (i) province or territory, (ii) community, (iii) reason for the evacuation (heart attack, prenatal care, child delivery, cancer treatment, etc.)? With regard to the regional development agencies, since January 1, 2020: what are the details of all contracts awarded to vendors located outside of Canada, broken down by (i) regional development agency, (ii) vendor, (iii) vendor location, including the postal code, the municipality, and the province, (iv) value, (v) description of the goods and services, including the volume, if applicable, (vi) the date the contract was signed, (vii) start and end dates? With regard to the tax rate paid by corporations to the Canadian Revenue Agency (CRA), broken down by fiscal year from 2015-16 to 2022-23: (a) what was the average effective tax rate paid by financial corporations broken down by revenue (i) above $100 million (ii) above $500 million, (iii) above $1 billion in revenue; (b) what was the average tax rate paid by oil and gas corporations, and oil and gas extraction corporations, broken down by revenue (i) above $10 million, (ii) above $100 million, (iii) above $500 million, (iv) above $1 billion; and (c) what was the average tax rate paid by real-estate corporations broken down by revenue (i) above $10 million, (ii) above $100 million, (iii) above $500 million, (iv) above $1 billion?

I thank the hon. member for Kingston and the Islands for his input on two important questions before the Chair, and the Chair will hasten to come back to the House with a decision, at least on one of those issues.

I am now ready to rule on the question of privilege raised on Wednesday, March 20, 2024, by the hon. member for Leeds—Grenville—Thousand Islands and Rideau Lakes concerning the 17th report of the Standing Committee on Government Operations and Estimates, which was presented to the House earlier that same day. The subject matter of this report is related to the committee's 14th report, which accused Mr. Kristian Firth and Mr. Darren Anthony of disregarding the rights and privileges of the committee to summon them to appear as witnesses. The House had concurred in that report, which ordered both to appear before the committee, and both have now done so. This new report arises from concerns over the testimony that Mr. Firth furnished to the committee and his refusal to answer members' questions. Having carefully listened to the members, acquainted myself with the content of the report and consulted the few but clear precedents, the Chair finds the matter to be a prima facie question of privilege. In his intervention, the parliamentary secretary to the leader of the government raised concerns about the motion that the member has indicated he will move. While it is perhaps true that the suggested remedy is not something we have seen for some time, I am of the view that it is procedurally in order. As with the case cited from June 2021, the motion provides for a call to the bar in order to be reprimanded, and a specific remedy to the offence. Furthermore, once proposed, the motion is subject to the usual rules of debate, and ultimately it is for the House to decide whether it agrees with the motion as proposed. I would now invite the member for Leeds—Grenville—Thousand Islands and Rideau Lakes to move his motion.

The amendment is in order. Questions and comments.

I have the honour to inform the House that messages have been received from the Senate informing the House that the Senate has passed the following bills: Bill C-34, an act to amend the Investment Canada Act; Bill C-67, an act for granting to His Majesty certain sums of money for the federal public administration for the fiscal year ending March 31, 2024; Bill C-68, an act for granting to His Majesty certain sums of money for the federal public administration for the fiscal year ending March 31, 2025. Resuming debate. The hon. member for Terrebonne.

I wish to inform the House that the hon. member for Terrebonne will have two minutes to respond to questions and comments when we resume this debate. Since the time provided for debate has expired for today, the House will resume consideration of the privilege motion on Monday, April 8, at 11 a.m. Pursuant to Standing Order 94, I wish to inform hon. members that private members' business will be suspended on that day. It being 2:30 p.m., the House stands adjourned until Monday, April 8, at 11 a.m., pursuant to Standing Orders 28(2) and 24(1). Let me take an opportunity to wish all members a happy Easter, a happy Passover and the end of Ramadan. (The House adjourned at 2:30 p.m.)